Treatment for diffuse large B-cell lymphoma (DLBCL) follows a risk-adapted approach, meaning the specific therapy depends on the patient’s age, overall health, molecular subtype, and how the disease responds to initial treatment. Most people are treated first with a combination of chemotherapy and an immune-targeting drug, and roughly 60 to 70 percent are cured with that frontline regimen alone. For those whose lymphoma comes back or doesn’t respond, the treatment path has changed dramatically in recent years with the arrival of CAR-T cell therapy and bispecific antibodies.
How Risk Is Assessed at Diagnosis
Before choosing a treatment plan, doctors calculate an International Prognostic Index (IPI) score. This scoring system, developed in 1993 and still the most widely used tool in DLBCL, assigns one point for each of five factors: age over 60, elevated blood levels of an enzyme called LDH (a marker of how fast the lymphoma is growing), a performance status indicating limited physical ability, advanced-stage disease (stage III or IV), and involvement of more than one organ or tissue site outside the lymph nodes. Scores range from 0 to 5, with higher numbers predicting a worse outlook.
Patients with a score of 0 or 1 generally have the best chance of being cured with standard treatment. Those with scores of 2 to 5 face higher risk and are more likely to be enrolled in clinical trials testing intensified or novel regimens. The IPI score is also the primary tool used to compare outcomes across different clinical trials, making it a common reference point in treatment decisions.
Doctors also classify DLBCL by its molecular subtype, most commonly into germinal center B-cell (GCB) or activated B-cell (ABC) types. This distinction matters because ABC DLBCL tends to respond less well to standard chemotherapy than GCB DLBCL. ABC tumors are driven by a constantly active survival signal inside the cancer cells that promotes growth and blocks cell death. GCB tumors, while generally more responsive to standard treatment, still fail in a meaningful number of patients.
First-Line Treatment
For decades, the backbone of DLBCL treatment has been R-CHOP: rituximab (an antibody that targets a protein called CD20 on the surface of lymphoma cells) combined with four chemotherapy drugs. This regimen is given in cycles, typically every 21 days for six cycles, followed by two additional doses of rituximab alone. It remains highly effective for many patients and is well studied across age groups.
A newer regimen called pola-R-CHP has emerged as an alternative for patients with intermediate or high-risk disease (IPI scores of 2 to 5). In this approach, one of the traditional chemotherapy drugs is swapped out for polatuzumab vedotin, an antibody-drug conjugate that delivers a cell-killing payload directly to lymphoma cells. A large international trial published in the New England Journal of Medicine found that pola-R-CHP improved the percentage of patients alive without disease progression at two years: 76.7% compared to 70.2% with standard R-CHOP. That translates to a 27% reduction in the risk of the lymphoma progressing, relapsing, or causing death. Both regimens follow the same six-cycle schedule.
Treating Elderly or Frail Patients
Full-dose R-CHOP can be too toxic for patients who are very old or who have significant heart, kidney, or lung problems. For these patients, a dose-reduced version called R-mini-CHOP is a practical option. In a study of patients aged 75 and older (with a median age of 83), R-mini-CHOP produced an overall response rate of 79%, with 53% achieving a complete response. Two-year overall survival was 63%, and the median duration of response was 44 months.
These numbers are lower than what younger, fitter patients achieve with full-dose treatment, but R-mini-CHOP allows elderly patients to receive effective therapy without the life-threatening side effects that full-dose chemotherapy can cause in this population. Age alone is not a reason to withhold aggressive treatment. Rather, decisions hinge on organ function, physical fitness, and the patient’s goals.
When the Lymphoma Comes Back or Doesn’t Respond
About 30 to 40 percent of DLBCL patients will have disease that either resists first-line treatment (called refractory disease) or comes back afterward (relapsed disease). How this is managed depends largely on the timing of the relapse and whether the patient can tolerate intensive therapy.
CAR-T Cell Therapy in the Second Line
For patients whose DLBCL is refractory to first-line treatment or relapses within 12 months, CAR-T cell therapy has become the preferred second-line option. CAR-T involves collecting a patient’s own immune cells, genetically engineering them in a lab to recognize and kill lymphoma cells, and infusing them back into the patient. Two CAR-T products are now approved for this setting. The approvals were based on trials (ZUMA-7 and TRANSFORM) showing these therapies outperformed the older approach of salvage chemotherapy followed by a stem cell transplant. When CAR-T was initially approved only for patients who had already failed two or more treatments, over 50% of those patients were still alive at five years, highlighting the durability of responses.
For patients who relapse after first-line therapy but are not healthy enough to undergo a stem cell transplant (due to older age, poor heart or lung function, or kidney problems), one CAR-T product is specifically approved based on results from the PILOT study, which showed an 80% overall response rate and a 54% complete response rate in transplant-ineligible patients.
Salvage Chemotherapy and Stem Cell Transplant
For patients who relapse more than 12 months after completing first-line therapy, the traditional approach remains salvage chemotherapy followed by autologous stem cell transplant (using the patient’s own stem cells). Common salvage regimens include R-ICE and R-DHAP, which produce overall response rates between 44% and 78% depending on the regimen and patient population. Only patients whose lymphoma shrinks with salvage chemotherapy (proving the disease is still sensitive to treatment) can proceed to transplant. Age over 65, on its own, is not a disqualifying factor for transplant as long as organ function and overall fitness meet the eligibility criteria.
Third-Line and Beyond
Patients whose lymphoma persists after two or more lines of therapy, or who relapse after CAR-T, have several newer options that didn’t exist just a few years ago.
Bispecific Antibodies
Bispecific antibodies are engineered proteins that grab onto both the lymphoma cell and the patient’s own immune T cells, forcing them into close contact so the T cell can destroy the cancer. Two are currently approved for DLBCL that has relapsed after at least two prior treatments. Both achieved complete response rates of about 40% in clinical trials, a notable result for patients who had already failed multiple therapies. These drugs require a careful step-up dosing schedule over the first few weeks to minimize the risk of a serious immune reaction called cytokine release syndrome. One of these agents is given for a fixed 12-cycle course, offering a defined treatment endpoint.
Antibody-Drug Conjugates
Loncastuximab tesirine is approved as a single agent for patients with DLBCL that has relapsed after two or more prior lines. It works by targeting CD19, a protein on the lymphoma cell surface, and delivering a potent cell-killing chemical directly into the cancer cell. It has shown durable responses even in patients considered difficult to treat. Its side effect profile is distinct from chemotherapy: the most notable concerns include skin reactions and sensitivity to sunlight, fluid retention, and liver enzyme elevations, all of which require monitoring but are generally manageable.
CNS Prophylaxis for High-Risk Patients
A small but serious risk with DLBCL is that the lymphoma can spread to the brain or spinal cord. The CNS International Prognostic Index stratifies this risk into three groups. Patients with scores of 0 to 1 have less than a 1% chance of central nervous system relapse at two years. Those with scores of 4 to 6 face a 12% risk, a meaningful concern given how difficult CNS lymphoma is to treat.
Whether to give preventive treatment (prophylaxis) remains genuinely debated. European guidelines recommend it for high-risk patients, particularly those with lymphoma involving the testicles, kidneys, or adrenal glands. U.S. guidelines are more cautious, suggesting only “consideration” of prophylaxis. The two main options are high-dose methotrexate given intravenously or chemotherapy injected directly into the spinal fluid. High-dose methotrexate is more commonly recommended but carries significant toxicity, particularly kidney damage. Some experts now favor the spinal fluid injection route for its better tolerability, reserving prophylaxis primarily for the highest-risk patients (CNS-IPI scores of 5 to 6, or disease in the testicles, kidneys, or adrenals) who have achieved remission after completing frontline treatment.
How Molecular Subtype Shapes Targeted Approaches
The molecular subtype of DLBCL is increasingly relevant beyond just prognosis. ABC DLBCL, which relies on a constantly active inflammatory survival pathway, has shown particular sensitivity to drugs that block that pathway. Drugs that inhibit a key signaling enzyme called BTK have produced impressive response rates specifically in relapsed ABC DLBCL, while having little effect on the GCB subtype. This makes molecular testing at diagnosis important for planning potential later-line strategies if the standard approach fails.
GCB DLBCL, despite its generally better response to chemotherapy, has its own biological vulnerabilities. These tumors often depend on a protein that normally helps immune cells develop in lymph nodes, and on a growth-promoting signaling pathway that can be targeted with specific inhibitors currently in clinical testing. For now, molecular subtype does not change the choice of first-line therapy, but it increasingly guides decisions when the disease relapses.